Bedaquilinefumarate , 10mMinDMSO , 845533-86-0
CAS NO.：845533-86-0
Empirical Formula: C36H35BrN2O6
Molecular Weight: 671.59
MDL number: MFCD28167761
| Pack Size | Price | Stock | Quantity |
| 1ml | RMB214.40 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| storage temp. | Inert atmosphere,Room Temperature |
| solubility | DMSO : 100 mg/mL (148.90 mM; Need ultrasonic)H2O : < 0.1 mg/mL (insoluble) |
| form | Powder |
| color | White to off-white |
| InChIKey | ZLVSPMRFRHMMOY-KZDJUSSONA-N |
| SMILES | C(/C(=O)O)=C\C(=O)O.[C@](C1=CC=CC2C=CC=CC1=2)(O)(CCN(C)C)[C@H](C1C=CC=CC=1)C1=CC2C=C(Br)C=CC=2N=C1OC |&1:8,25,r| |
Description and Uses
Bedaquiline fumarate (BQF) is an FDA-approved antituberculosis drug that targets the enzyme ATP synthase. It is a fumarate salt prepared from equimolar amounts of bedaquiline and fumaric acid. It can be used in combination therapy for the treatment of multidrug-resistant tuberculosis in the lungs of adults (18 years of age and older). The new BQF microemulsion dosage form of BQF has improved oral bioavailability over the previous formulation, and the BQF microemulsion is cytocompatible with significantly higher cellular uptake than the control group at the highest concentration of 500 μg/ml, which could lead to further use in the effective treatment of multidrug-resistant tuberculosis[1].
Safety
| Symbol(GHS) |  GHS07 |
| Signal word | Warning |
| Hazard statements | H302-H315-H319-H335 |
| Precautionary statements | P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501 |
